Hunter syndrome drug safety tracked in extended trial
NCT ID NCT06031259
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is a follow-up for people with Hunter syndrome and cognitive problems who already took part in earlier studies. It aims to check the long-term safety of the drug idursulfase-IT given with Elaprase. About 6 children and adults will continue their same treatment to monitor for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTER SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopital Femme Mere Enfant
Bron, Auvergne-Rhône-Alpes, 02 69229, France
-
Hospital for Sick Children
Toronto, Ontario, M5G1X8, Canada
-
M.A.G.I.C. Clinic
Calgary, Alberta, T2E 7Z4, Canada
-
University of British Columbia
Vancouver, British Columbia, V6T1Z3, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Lifeline for hunter syndrome patients: continued access to Brain-Targeting therapy
- Early enzyme therapy may help kids with rare disease grow better
- Home infusions may help patients stick to treatment
- Hunterase extended trial shows promise for managing hunter syndrome
- New stem cell approach aims to tame rare genetic diseases
- Hunter syndrome study pulled before it even started